Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T cell-tumor cell: a fatal interaction?

D B Chappell1, N P Restifo

  • 1The Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Bethesda MD 20814, USA.

Cancer Immunology, Immunotherapy : CII
|October 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Gene therapy·2015
Same author

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Gene therapy·2012
Same author

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.

Gene therapy·2008
Same author

B16 as a mouse model for human melanoma.

Current protocols in immunology·2008
Same author

Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Cancer research·2001
Same author

Immunization against endogenous retroviral tumor-associated antigens.

Cancer research·2001
Same journal

CXCL13-CXCR5 signaling in CD8<sup>+</sup> T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

Cancer immunology, immunotherapy : CII·2026
Same journal

Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.

Cancer immunology, immunotherapy : CII·2026
Same journal

Correction: Repurposing public sarcoma multi-omics for neoantigen discovery.

Cancer immunology, immunotherapy : CII·2026
Same journal

A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.

Cancer immunology, immunotherapy : CII·2026
See all related articles

The Fas/FasL system regulates cell death and survival. Tumor cells expressing Fas Ligand (FasL) may indicate uncontrolled proliferation and T cell deletion, establishing immune privilege.

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Biology

Background:

  • Fas (Apo-1/CD95) initiates apoptosis via caspase cascades.
  • The Fas/FasL system is known to dampen immune responses by deleting activated T cells.
  • Tumor cells are proposed to express FasL to evade immune surveillance.

Purpose of the Study:

  • To review the role of Fas/FasL interactions in modulating antitumor responses.
  • To critically evaluate evidence for FasL expression by tumor cells.
  • To explore alternative explanations for observed FasL phenomena in vitro and in vivo.

Main Methods:

  • Literature review of published data.
  • Analysis of laboratory-generated data.
  • Critical examination of in vitro and in vivo experimental findings.

Related Experiment Videos

Main Results:

  • The Fas/FasL system acts as a general autocrine mechanism for regulating cell survival and expansion.
  • Tumor cell FasL expression is not consistently proven and may have alternative explanations.
  • Observed FasL expression in tumors suggests a disruption in proliferation control.

Conclusions:

  • The Fas/FasL system is a fundamental regulator of cell fate.
  • Tumor cell FasL expression is linked to dysregulated proliferation and immune evasion.
  • Immune privilege in tumors can arise from activation-induced cell death of T cells.